Cyfuse Biomedical K.K. Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2018
Net Income	-761	-869	-586	-471	-	Upgrade
Depreciation & Amortization	37	38	40	63	-	Upgrade
Other Operating Activities	80	43	124	5	-	Upgrade
Change in Accounts Receivable	15	-3	-3	44	-	Upgrade
Change in Inventory	-33	-9	-5	21	-	Upgrade
Change in Accounts Payable	49	22	-20	-3	-	Upgrade
Change in Other Net Operating Assets	79	18	-112	-62	-	Upgrade
Operating Cash Flow	-534	-760	-562	-403	-	Upgrade
Capital Expenditures	-47	-8	-19	-228	-	Upgrade
Investment in Securities	-350	-	-	-200	-	Upgrade
Other Investing Activities	-	-	-	-2	-	Upgrade
Investing Cash Flow	-397	-8	-19	-430	-	Upgrade
Short-Term Debt Issued	-	-	73	328	-	Upgrade
Long-Term Debt Issued	489	-	-	90	-	Upgrade
Total Debt Issued	489	-	73	418	-	Upgrade
Short-Term Debt Repaid	-32	-51	-	-	-	Upgrade
Long-Term Debt Repaid	-18	-18	-77	-82	-	Upgrade
Total Debt Repaid	-50	-69	-77	-82	-	Upgrade
Net Debt Issued (Repaid)	439	-69	-4	336	-	Upgrade
Issuance of Common Stock	817	17	22	2,329	-	Upgrade
Other Financing Activities	-	-	-	-7	-	Upgrade
Financing Cash Flow	1,256	-52	18	2,658	-	Upgrade
Miscellaneous Cash Flow Adjustments	-2	-1	-	-1	-	Upgrade
Net Cash Flow	323	-821	-563	1,824	-	Upgrade
Free Cash Flow	-581	-768	-581	-631	-	Upgrade
Free Cash Flow Margin	-252.61%	-1422.22%	-952.46%	-168.72%	-	Upgrade
Free Cash Flow Per Share	-66.01	-95.40	-74.37	-236.54	-	Upgrade
Cash Interest Paid	14	9	9	7	-	Upgrade
Cash Income Tax Paid	2	2	2	2	-	Upgrade
Levered Free Cash Flow	-483.5	-585.25	-446.88	-458	-	Upgrade
Unlevered Free Cash Flow	-474.13	-579	-440.63	-453.63	-	Upgrade
Change in Working Capital	110	28	-140	-	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.